MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
about
Vaccine adjuvants as potential cancer immunotherapeuticsBiomarkers for glioma immunotherapy: the next generationSafety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic reviewCurrent status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules.Rapid evolution of cancer/testis genes on the X chromosome.Fusion of Hsp70 to Mage-a1 enhances the potency of vaccine-specific immune responsesEvolutionary history of the cancer immunity antigen MAGE gene family.MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies.Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcelluloVaccine Potentiation by Combination AdjuvantsRandomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease AfterAn integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer.Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer.Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.Recent advances and hurdles in melanoma immunotherapy.Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.Metastatic melanoma and immunotherapyCancer testis antigen and immunotherapy.Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.Heterogeneous expression of melanoma antigen (hMAGE) mRNA in mesenchymal neoplasia.Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696).Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma.Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.
P2860
Q26752522-67B14869-DE37-4E41-8520-D3A2A5C99DF4Q26825496-33D842F8-9FE7-4A81-8865-FF62CF841EE9Q28084805-79B976C7-7A1C-4486-B73F-D65B919536D1Q30412300-E261F557-0C4B-4B08-82B5-23DC7F392722Q30425111-AB5CDF40-2DCA-471C-B63C-19D89B0DBD30Q30429708-B70604AB-90FA-4781-8ED0-09B76A7A8F80Q30430002-2EE98859-9765-4EC6-9958-80E2EBC6D6FEQ30434822-C92083EA-9A21-4ED4-AEAE-5757D92D26B7Q30446891-A822A896-9432-479F-A4E0-15D27E43711EQ33285549-D42E6DE7-9D9F-4097-A8DE-771ADD3066B2Q33643966-85343BCB-1EF4-43AE-AB57-0A530B47BE8AQ33939709-4B8628E0-2B3F-46A4-9070-FD6855F59BDDQ34196069-526A40DB-F93B-48FD-9079-F03F2C06FE47Q34666875-CB74EEE7-B63C-4766-8B93-0A4964965DABQ35826767-CDCB6272-A4E7-4573-A16C-C52E3135014EQ36346631-3E6C14E1-95D5-46CC-AD9E-5231D08A761CQ36476387-4B8E9833-8EFD-4943-9C09-500B9B2A1EBDQ36547213-95DDDC07-490C-489B-852C-C1DD4B88F1F6Q36785925-612C913D-AC1F-48FB-A779-7A86EA3D48BDQ37216571-3DCF7131-E8C8-4A65-832A-37DBA7350CA1Q37309281-58E86043-BDB4-4115-8E60-E6BE1A408BA5Q37382380-1D1C6FE1-8889-415F-B9C4-1D16CB449DD0Q37593172-1D654015-D265-46D2-819D-383369BB7B4DQ37873932-53B22A4D-B20F-4439-AE2C-58C075D86745Q38261273-7A8A44B5-6A24-46A7-B08C-48C8826CF679Q38693404-60296C99-C37A-4C60-8B2C-BC0542E7BF80Q38901338-D6EC39BB-72E9-482C-B14D-4E38D81AD05AQ38912232-9C222D7D-94A2-49E7-8F76-9DD135F76FC4Q38948541-BF90E8DD-88A1-45EB-B5B1-06CAC06ECABDQ38992236-3C378C9C-A113-4793-8033-A43F407D48DCQ39019419-A666F93C-43B4-4E36-9CF5-3C7C0EB328E0Q39533432-70BA486D-A3CA-4227-90BC-0C87F8CE4FB1Q40267997-211A194B-6491-473A-90C1-364C001D1A0EQ40841838-82C86594-F833-4A16-AEDC-40D0749C7FAFQ41169564-F0E523B7-6245-4D90-AD2F-1F09448FC752Q45073466-4DD9817C-8270-44C7-B803-F3DD820C22F2Q45872230-C1A87B70-28FC-49C5-8C09-8B3B904F82ABQ46820235-3ECE57CD-D96D-4D08-B0F0-BFF7F4A72867Q53491955-F3E1C392-F4C9-49E5-A016-6075B0D6A580Q53641322-35BFFFF0-7237-4738-ABDF-69880AA3D35F
P2860
MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
MAGE-A1-, MAGE-A10-, and gp100 ...... ipeptide vaccine for melanoma.
@ast
MAGE-A1-, MAGE-A10-, and gp100 ...... ipeptide vaccine for melanoma.
@en
type
label
MAGE-A1-, MAGE-A10-, and gp100 ...... ipeptide vaccine for melanoma.
@ast
MAGE-A1-, MAGE-A10-, and gp100 ...... ipeptide vaccine for melanoma.
@en
prefLabel
MAGE-A1-, MAGE-A10-, and gp100 ...... ipeptide vaccine for melanoma.
@ast
MAGE-A1-, MAGE-A10-, and gp100 ...... ipeptide vaccine for melanoma.
@en
P2093
P1476
MAGE-A1-, MAGE-A10-, and gp100 ...... ipeptide vaccine for melanoma.
@en
P2093
Catherine J Wiernasz
Cheryl Murphy
Courtney Garbee
Elizabeth M H Woodson
Eric A Bissonette
Galina Yamshchikov
Gina R Petroni
James W Patterson
Jennifer Pressley
Patrice Y Neese
P304
P356
10.4049/JIMMUNOL.174.5.3080
P407
P577
2005-03-01T00:00:00Z